Abzena has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases.   Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory diseases, including juvenile idiopathic arthritis. The 18-month program includes: development of a research cell bank using Abzena’s proprietary cell line and ambr 15 automated high throughput bioreactors, generation of m...